Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

rstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) reported data from the Phase I clinical trial program for XL880, a novel small molecule compound that simultaneously inhibits MET and VEGFR2, targets implicated in tumor growth, tumor cell migration, and angiogenesis. Patricia M. LoRusso, D.O., Director of the Phase I Clinical Trials Program at the Barbara Ann Karmanos Cancer Institute, Professor of Hematology and Oncology at Wayne State University, and a lead investigator in the trial, presented the data in the Developmental Therapeutics: Molecular Therapeutics oral abstract session (Abstract #3526) at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

The data presented were taken from two Phase I studies of XL880 in patients with advanced solid tumors. One study evaluated an intermittent, weight-based dosing regimen and the other evaluated fixed daily dosing. Both studies included pharmacokinetic, pharmacodynamic, and tumor response analyses.

Five partial responses (>30% tumor regression by RECIST) were observed, including three in papillary renal cell cancer, one in medullary thyroid cancer, and one in hurthle cell thyroid cancer. Tumor shrinkage of less than 30% or prolonged stable disease of greater than 3 months was observed in an additional 20 patients. Additionally, in a best response evaluation as determined by RECIST criteria, investigators reported that 39 of 45 patients in the combined phase 1 studies had either tumor regression or stable disease.

"We consider the number of patients with responses or disease stabilization in these studies to be quite striking, particularly in light of these patients' advanced disease," said Dr. LoRusso. "We believe XL880 has significant potential as a novel cancer therapy, and the ongoing Phase II trials should provide important insight into the late stage development plans for the compound."

Histological analyses of tumor samples from four patients showed decreases in the ph
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:4/28/2015)... Fla. , April 28, 2015 /PRNewswire/ ... is pleased to announce a partnership with ... radio frequency identification (RFID) storage and transport ... and Terso to enhance capabilities and provide ... iTraycer is a comprehensive inventory management system ...
(Date:4/28/2015)... 28, 2015  Clinicians from the Veterans Affairs Medical ... demonstrate that Leaf Healthcare,s new, wireless patient monitoring system ... prevention turn protocols. Their presentation will take place at ... San Antonio, Texas , April 29-May 3. ... "Optimizing patient turning resources by using a novel wearable ...
(Date:4/28/2015)... April 28, 2015 Exagen Diagnostics, Inc., ... significant unmet need for the accurate diagnosis and ... announced today that its Avise SLE+ Connective Tissue ... orders since launch, and that adoption continues to ... identifying Connective Tissue Disease (CTD), including, but not ...
Breaking Medicine Technology:Medical Tracking Solutions, Inc., Partners with Terso Solutions, Inc. 2VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 2VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 3VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 4Exagen Sees Growing Adoption of Avise Diagnostic for Connective Tissue Disease with New Milestone 2
... Aug. 2 Cytokine PharmaSciences,Inc. (CPSI) today ... inhibitors showed oral efficacy in animal models. ... it is advancing one of these compounds,into ... or MIF, is linked to many,conditions, including ...
... ARBOR, Mich., Aug. 3 Far more of today,s,heart attack ... clogged heart arteries than even a,decade ago, a new study ... from this urgent treatment,-- which is known to save lives ... it at all, the study shows. And the chance ...
Cached Medicine Technology:Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2Many Heart Attack Patients Don't Get Best Emergency Treatment 2Many Heart Attack Patients Don't Get Best Emergency Treatment 3Many Heart Attack Patients Don't Get Best Emergency Treatment 4
(Date:4/28/2015)... Georgia State University’s School of Public Health has ... with the school on efforts to improve policies and ... more tobacco and has more smokers than any other ... Partnership-Tobacco Free Cities, will focus on a group of ... control efforts and where public health organizations are in ...
(Date:4/28/2015)... 2015 Tools4ever, the market leader ... today that they have been chosen by IT ... Identity and Access Management vendors. IT Central Station ... and Access Management tools by real users in ... analyzed their trends to come up with the ...
(Date:4/28/2015)... 2015 A new survey from National ... damage, 66 percent of Americans fear brain damage the most. ... Month in May, shed light on the need for greater ... prevent a stroke. By controlling modifiable risk factors, 80 ... is a “ brain attack ” that occurs when blood ...
(Date:4/28/2015)... April 28, 2015 A first-in-human ... of Molecular Imaging and Biology showed initial safety, ... generation fluorine-18 labeled small-molecule PSMA inhibitor. The imaging ... in Baltimore, MD by study co-author, Martin G. ... evaluation of [18F]DCFPyL demonstrated a number of important ...
(Date:4/28/2015)... 2015 Colorado spine surgeon Donald Corenman, ... his popular spine education website NECKANDBACK.COM and ... eMedical Media. This website has been redesigned to help ... the spine, causes of neck and back pain, and ... website and personally answers questions in the neck and ...
Breaking Medicine News(10 mins):Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Tools4ever Chosen as Part of “Top Identity and Access Management Tools - 2015 Edition” 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 3Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3
... case of dubious consolation, nineteen persons infected with AIDS ... Chinas most moneyed lawsuit//. This money should provide some ... of them are living in poverty. ,Fifteen persons ... out at a provincial hospital of northern China in ...
... of Neurological disorders in their early stage or ... ,Melbourne researchers have found a relationship between ... roses and bleach and neurological disorders such as ... of the Melbourne Neuropsychiatry Clinic, Christos Pantelis said, ...
... protein that causes a brain wasting disease called Creutzfeld-Jakob can ... glucose in the blood stream. ,According to the ... disease on the regulatory mechanism of blood glucose. The protein ... found as a twisted, deformed protein during the disease. ...
... dogs along with presence of a certain types of ... new study//., ,David Bernstein, professor of immunology at ... after studying about 500 infants, reported online edition of ... with a higher risk of developing allergies and asthma ...
... extensive research that spanned over 3 decades was conducted ... stand the risk of mental illnesses such as schizophrenia,// ... Women without children were seldom seen admitted in psychiatric ... times more risk than those who do not have ...
... Researchers have started creating an online global map called as ... exactly highlighting the// areas where the disease is most likely ... Institute are supporting the project. ,It is reported ... nearly 40 per cent of the world's population is at ...
Cached Medicine News:Health News:Detection of Neurological Disorder is Just a Sniff Away!! 2Health News:Juvenile Diabetes may Be Caused by Mad Cow Protein 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: